Morningstar recommends a ‘hold’ position on drug company Acrux, with a high fair value uncertainty on its price. The fair value expectation at present is $2.00.
Morningstar recommends a “hold" position on drug company Acrux , with a high fair value uncertainty on its price. The fair value expectation at present is $2.00.
“Acrux is trialling a range of applications of its patented transdermal drug delivery technology. These include treatments for menopause, sexual dysfunction, nausea and a contraceptive application," Morningstar analysts said.
